Background
==========

Ductal carcinoma *in situ*(DCIS) is thought to be a precursor of invasive ductal carcinoma (IDC) and is defined as a lesion in which cancer cells do not grow beyond the basal membrane of the mammary duct \[[@B1]\]. Since the introduction of mammography in breast cancer screening, increasing numbers of DCIS are now being identified \[[@B2]\]. About 10 years ago, DCIS accounted for only 1--5% of all newly diagnosed cases of breast cancer, whereas the frequency has increased recently to 15--20% \[[@B3],[@B4]\]. According to the criteria of the American Joint Committee on Cancer (AJCC), IDC with a microscopic focus of invasion less than or equal to 0.1 cm in the longest dimension, is defined as T1mic \[[@B5]\]. In situations where there are multiple foci of microinvasion, the classification is based on the largest focus, rather than the sum of all the individual foci and therefore, if the size of the largest focus is less than 0.1 cm, the lesion will still be defined as T1mic \[[@B5]\]. This ductal carcinoma *in situ*with microinvasion, known as DCIS-Mi, is identified in 10--20% of cases thought to be DCIS, through the use of preoperative diagnostic imaging and cytology; it is considered to represent the interim stage in the progression from DCIS to IDC \[[@B6]-[@B8]\]. Histopathological factors including architectural subtypes, nuclear grade, the presence of necrosis, tumor size, and the distance to the surgical stump have already been reported as predictors of the risk of local recurrence in DCIS \[[@B9]-[@B11]\]. Further analyses of the biological parameters will make the prediction of local recurrence in DCIS more accurate. At present, various biological parameters have been reported as prognostic factors for DCIS. Overexpression of human epidermal growth factor receptor 2 (HER2), decreased expression of estrogen receptor (ER), overexpression of p53, and positive Ki-67 staining, have all been shown to correlate with nuclear grade in both DCIS and IDC \[[@B8],[@B12]-[@B16]\]. It has also been reported that endometase/matrilysin-2 and tissue inhibitors of metalloproteinase-2 and -4 are overexpressed in the invasive component of DCIS \[[@B17]\]. However, there have been few reports investigating the status of apoptosis and apoptosis-related factors in DCIS. In particular, the *survivin*gene, shown to be expressed in proliferating cells such as fetal and various cancer cells, is known to be a member of the inhibitor of apoptosis protein (IAP) family, which promotes cell proliferation and inhibits apoptosis \[[@B18]-[@B21]\].

Tumor progression may be induced or associated by alterations in the proliferative capacity and the apoptosis potential, and the findings may find some basic and applied interpretations especially useful for confirming a diagnosis, and in building up prognostic criteria. Therefore, apoptosis-related factors (apoptotic index, survivin, Bcl-2, Bax), cell proliferation/cycle-related factors (Ki-67, p53, p21, cyclinD1, Rb), and other factors are analyzed in DCIS and DCIS-Mi in this investigation.

Methods
=======

Patients
--------

The study population consisted of 52 patients with DCIS and 28 with DCIS-Mi, diagnosed by postoperative histopathological examinations after undergoing surgery for the diagnosis of non-invasive or invasive ductal carcinoma of the breast at the Kumamoto University Hospital or the Nagoya City University Hospital from 1990 to 2005. The median age was 56 years old (range, 36--86) in patients with DCIS and 50 (range, 32--71) in patients with DCIS-Mi. The median follow-up period was 62 months (range, 13--140) in DCIS and 54 (range, 14--182) in DCIS-Mi (Table [1](#T1){ref-type="table"}). To date, of the DCIS-Mi patients, one has had a recurrence in the contralateral breast and another has developed bone metastasis. There have been no deaths. The information was obtained from the patient records. The ethics committee of Kumamoto University and Nagoya City University approved the study protocol and confirmed that it was conducted in accordance with the guidelines of the 1975 Declaration of Helsinki. Informed consent was obtained from all patients before or after surgery. Histological diagnosis was made by 2 specialized pathologists. The histological subtypes were determined on the predominant area occupying most of the lesion, although in some cases multiple histological subtypes were mixed. When there were multiple foci of microinvasion, if the size of the largest focus was less than 0.1 cm, the lesion was regarded as DCIS-Mi.

Histological variables, including classification of histological subtypes, grade of nuclear atypia, and the presence of necrotic foci, were evaluated on slides stained with hematoxylin-eosin (HE). According to the Van Nuys classification \[[@B22]\], cases were classified into three groups: high-nuclear grade (Grade 3); non-high nuclear grade with necrosis (Grade 2); and non-high nuclear grade without necrosis (Grade 1). In some cases, microinvasion was confirmed by staining the basal membrane with type IV collagenase \[[@B23]\].

###### 

Histological characteristics of intraductal component in ductal carcinoma *in situ*(DCIS) and in ductal carcinoma *in situ*with microinvasion (DCIS-Mi)

                                            **DCIS**      **DCIS-Mi**    
  ----------------------------------------- ------------- -------------- ---------------------
  Number of patients                        52            28             
  Median follow-up period, months (range)   62 (3--140)   54 (14--182)   
  Median age, years (range)                 56 (36--86)   50 (32--71)    
  Architectural classification                                           
   comedo                                   8 (15.4%)     10(35.7%)      *P*= 0.073
   Papillary                                21 (40.4%)    10 (35.7%)     (comedo *vs*others)
   cribriform                               15 (28.8%)    4 (14.3%)      
   solid                                    4 (7.7%)      4 (14.3%)      
   low papillary                            4 (7.7%)      0 (0)          
  Nuclear Grade                                                          
   Grade 1                                  21 (40.4%)    7 (25)         *P*= 0.16
   Grade 2                                  29 (55.8%)    18 (64.3)      (1 vs. 2,3)
   Grade 3                                  2 (3.9%)      3 (10.7)       
  Necrosis                                                               
   absent                                   25 (48.1%)    4 (14.3%)      *P*= 0.0017
   Present                                  27 (51.9%)    24 (85.7%)     
  Van Nuys Classification\*                                              
   Grade 1                                  25 (48.1%)    4 (14.3%)      *P*= 0.0017
   Grade 2                                  25 (48.1%)    21 (75%)       (1 vs. 2,3)
   Grade 3                                  2 (3.9%)      3 (10.7%)      

\* Van Nuys Classification: Grade 1 = non-high nuclear grade without necrosis; Grade 2 = non-high nuclear grade with necrosis; Grade 3 = high-nuclear grade.

Immunohistochemistry
--------------------

Resected specimens were fixed in 10% buffered-formalin and embedded in paraffin within 24--48 hours. Four-μm sections were cut from this paraffin block and mounted on adhesive-coated slides (Aminosilane-coated slides; MATSUNAMI GLASS Co. Ltd., Japan) for immunohistochemistry \[[@B15]\]. The sections were deparaffinized in xylene (5 × 5 minutes) and ethanol (2 × 100%, 1 × 90%, 1 × 80%, 1 × 70%). Subsequently, antigen retrieval was performed in citrate buffer at pH 9 for survivin as previously described \[[@B24]\], using a microwave oven (after boiling, 3 × 10 minutes at 750W or 4 × 15 minutes at 170W). After leaving at room temperature for 20 minutes, sections were immersed in phosphate-buffered saline (PBS). Endogenous peroxidase was blocked by incubation with 3% H~2~O~2~in methanol for 10 minutes. Sections were washed with PBS (3 × 5 minutes) followed by blocking with 5% skimmed milk for 20 minutes \[[@B25]\].

Immunohistochemical staining was performed by the avidin-biotin complex (ABC) method using the Vectastain ABC kit for ER, progesterone receptor (PgR), HER2, Ki-67, survivin, p53, p21, cyclin D1, and Rb, (monoclonal antibodies, DAKO, Netherlands) and by the immuno-enzyme polymer method (indirect method, EnVision system, DAKO, Netherlands) using Histofine Simple Stain MAX PO (Nichirei Bioscience, Tokyo Japan) for Bcl-2 and Bax \[[@B26]\]. Sections were incubated with dilutions of primary antibodies for 60 minutes at room temperature. After washing with PBS (3 × 5 minutes), sections were incubated with biotinylated secondary antibodies for 30 minutes. Following this, the sections were washed again with PBS (3 × 5 minutes) and then reacted with an ABC solution for 30 minutes at room temperature. After a further washing with PBS (3 × 5 minutes), the sections were stained with 3, 3\'-diaminobenzidine (DAB) substrate solution.

In the immuno-enzyme polymer (indirect) method, sections were incubated with dilutions of primary antibodies at 4°C overnight. After washing with PBS (3 × 5 minutes), sections were reacted with the Histofine Simple Stain MAX PO (mouse or rabbit), washed again with PBS (3 × 5 minutes), and then stained with DAB solution \[[@B25]\]. Nuclear staining of all sections was done with hematoxylin. The sections were mounted after dehydration (1 × 70%, 1 × 80%, 1 × 90%, 2 × 100% ethanol) and penetration (3 × xylene for 3 minutes). Details of the primary antibodies used in this study are shown in Table [2](#T2){ref-type="table"}.

###### 

Details of immunohistochemistry and the antibodies

  **Antibody**   **Source**   **Clone**   **Dilution**   **Pretreatment**   **Citrate buffer**   **Incubation**   **Detection system**
  -------------- ------------ ----------- -------------- ------------------ -------------------- ---------------- ----------------------
  ER             DAKO         1D5         1/50           4 × 15 min MW      pH6                  1 h RT           ABC
  PgR            DAKO         636         1/800          4 × 15 min MW      pH6                  1 h RT           ABC
  HER2           DAKO                     1/300          4 × 15 min MW      pH6                  1 h RT           ABC
  Ki-67          DAKO         MIB-1       1/50           3 × 10 min MW      pH9                  1 h RT           ABC
  Bcl-2          DAKO         124         1/50           3 × 10 min MW      pH9                  ON 4°C           En-Vision
  Bax            DAKO                     1/50           3 × 10 min MW      pH6                  ON 4°C           En-Vision
  Survivin       SantaC       D-8         1/50           3 × 10 min MW      pH9                  1 h RT           ABC
  p53            DAKO         DO-7        1/50           3 × 10 min MW      pH9                  1 h RT           ABC
  p21            DAKO         SX118       1/25           3 × 10 min MW      pH9                  1 h RT           ABC
  cyclinD1       NovoC        P2D11F11    1/50           3 × 10 min MW      pH9                  1 h RT           ABC
  Rb             NovoC        13A10       1/100          3 × 10 min MW      pH6                  1 h RT           ABC

ER = estrogen receptor; PgR = progesterone receptor; MW = microwave; RT = room temperature; ON = overnight; Santa C = Santa Cruz; NovoC = NovoCastra.

Evaluation of immunohistochemistry
----------------------------------

For Ki-67 expression, the percentage of cancer cells with positively-stained nuclei was determined. Nuclear labeling of more than 10% of all observed cancer cells was regarded as positive for ER, PgR, p53, p21, cyclin D1, and Rb \[[@B25]\]. HER2 expression was categorized into no staining (0), weak staining (+1), moderate staining (+2), or strong staining (+3), and was regarded as positive only when cancer cells showed strong staining (+3) \[[@B15]\]. Staining of more than 5% of all observed cancer cells was regarded as positive for survivin, Bcl-2, and Bax \[[@B20],[@B27]\].

Apoptosis
---------

Apoptosis was detected by the TdT-mediated dUTP-biotin nick end labeling (TUNEL) method using ApopTag Peroxidase In Situ Apoptosis Detection Kit (S7100; Chemicon International, CA, USA) \[[@B28]\]. After deparaffinization, sections were incubated with Proteinase K for 15 minutes at room temperature and immersed in pure water. After this, the sections were incubated with 3% H~2~O~2~for 5 minutes at room temperature followed by washing with PBS (2 × 5 minutes). Sections were incubated with equilibration buffer for at least 10 minutes at room temperature and then with working strength TdT enzyme at 37°C for 60 minutes, at which point the sections were incubated with working strength stop/wash buffer for 10 minutes after being agitated for 15 seconds at room temperature, followed by washing with PBS (2 × 1 minute). Sections were then incubated with anti-digoxigenin conjugate for 30 minutes at room temperature followed by washing with PBS (4 × 2 minutes). Sections were stained with DAB solution, dehydrated, and mounted. To quantitate apoptosis, the mean number of positive nuclei per 1000 counted nuclei/field was determined in three fields within the cancerous areas of the intraductal components. The mean number of positive nuclei was defined as the apoptotic index.

Statistical methods
-------------------

The statistical tests were utilized to examine the difference in each factor between DCIS and DCIS-Mi. Quantitative analyses (Ki-67 and apoptotic index) were performed using the Mann-Whitney U test; all other factors were analyzed with the Chi-squared test and Fisher\'s exact test. For all comparisons, differences were considered significant when the *P*-value was less than 0.05. Statistical analyses were performed using the statistical software JMP Japanese Version 4.0 (SAS).

Results
=======

Histological evaluation
-----------------------

Results showed that the comedo type tended to be found more frequently in DCIS-Mi (36%) than in DCIS (18%), although this difference did not reach statistical significance (*P*= 0.073). There was no difference in nuclear grade between the two groups but a necrotic focus was found at a significantly higher frequency in DCIS-Mi (85.7%) than in DCIS (51.9%) (*P*= 0.0017). According to the Van Nuys classification, which evaluates both nuclear grade and necrosis, the grade of malignancy was significantly higher in DCIS-Mi (14.3%, Grade 1) than in DCIS (48.1%, Grade 1) (*P*= 0.0017, Grade 1 *vs*. Grade 2 and 3) (Table [2](#T2){ref-type="table"}).

Relative expression of hormone receptors, HER2, and Ki-67: DCIS vs. DCIS-Mi
---------------------------------------------------------------------------

There was no significant difference between DCIS and DCIS-Mi in expression levels of universal biological factors such as ER, PgR, and HER2. The Ki-67 index tended to be higher in DCIS-Mi (22.8 ± 2.0%) than in DCIS (17.9 ± 1.5%), although the difference was not statistically significant (*P*= 0.052) (Table [3](#T3){ref-type="table"}). Representative microscopic views of immunohistochemical detection were shown in Fig. [1](#F1){ref-type="fig"}.

###### 

Hormone Receptor status, HER2 status and Ki-67 index in DCIS and DCIS-Mi

                          **DCIS**     **DCIS-Mi**   ***P*-value**
  ----------------------- ------------ ------------- ---------------
  Estrogen Receptor                                  
   positive               38 (73.1%)   19 (67.9%)    0.62
   negative               14 (26.9%)   9 (32.1%)     
  Progesterone Receptor                              
   positive               37 (71.2%)   16 (57.1%)    0.21
   Negative               15 (28.9%)   12 (42.9%)    
  c-erbB-2                                           
   0, 1+,2+               43 (82.7%)   22 (78.6%)    0.65
   3+                     9 (17.3%)    6 (21.4%)     
  Ki-67 index                                        
   positive rate %        17.9 ± 1.5   22.8 ± 2.0    0.052
   mean ± SD                                         

DCIS = ductal carcinoma *in situ*; DCIS-Mi = ductal carcinoma *in situ*with microinvasion; SD = standard deviation.

![**Representative microscopic views of immunohistochemical detection.** Intraductal component found in patients with DCIS, using **A**. hematoxylin-eosin (HE) staining, the frames show cells stained for **B**. estrogen receptor (ER), **C**. HER2, **D**. Ki-67, **E**. p21, **F**. BCL-2, **G**. BAX, and **H**. Survivin 1, respectively. **I**. Survivin 2 shows moderately positive Survivin staining detected in another patient with DCIS. (original magnification × 200)](1471-2407-8-287-1){#F1}

Relative expression of apoptosis-related markers: DCIS vs. DCIS-Mi
------------------------------------------------------------------

The relative expressions of the apoptosis-related markers in DCIS and DCIS-Mi are shown in Table [4](#T4){ref-type="table"}. Apoptotic index tended to be higher in DCIS-Mi (0.29 ± 0.06%) than in DCIS (0.17 ± 0.04%) (*P*= 0.082). The expression of Bax, a promoting factor of apoptosis, was significantly higher in DCIS-Mi (96.4%) than in DCIS (71.2%) (*P*= 0.0028). The expression of survivin, an inhibiting factor of apoptosis, was also significantly higher in DCIS-Mi (85.7%) than in DCIS (55.8%) (*P*= 0.0048), while the expression of another apoptosis inhibitor (Bcl-2) tended to be found more frequently in DCIS-Mi (78.6%) than in DCIS (58.8%), although this did not reach statistical significance (*P*= 0.071). There was no difference in the expression levels of p53, p21, cyclin D1, and Rb between DCIS and DCIS-Mi (Table [4](#T4){ref-type="table"}). Because no cases were detected showing nuclear staining of survivin, in this study cases were regarded positive only when cytoplasmic staining was detectable. Based on this limitation the survivin expression showed a positive correlation with Bax expression (*P*= 0.038) and cases positive for survivin tended to show a higher apoptotic index (*P*= 0.077) (Table [5](#T5){ref-type="table"}).

###### 

Apoptosis-related factors in DCIS and DCIS-Mi

                             **DCIS**     **DCIS-Mi**   ***P*-value**
  -------------------------- ------------ ------------- ---------------
  Apoptotic Index (N/1000)   1.7 ± 0.4    2.9 ± 0.6     0.082
                                                        
  Bcl-2                                                 
   negative                  21 (41.2%)   6 (21.4%)     0.071
   Positive                  30 (58.8%)   22 (78.6%)    
  Bax                                                   
   negative                  15 (28.8%)   1 (3.6%)      0.0028
   Positive                  37 (71.2%)   27 (96.4%)    
  Survivin                                              
   negative                  23 (44.2%)   4 (14.3%)     0.0048
   positive                  29 (55.8%)   24 (85.7%)    
  p53                                                   
   positive                  39 (76.5%)   23 (82.1%)    0.55
   Negative                  12 (23.5%)   5 (17.9%)     
  p21                                                   
   positive                  36 (69.2%)   15 (53.6%)    0.17
   negative                  16 (30.8%)   13 (46.4%)    
  cyclinD1                                              
   positive                  36 (70.6%)   18 (64.3%)    0.57
   Negative                  15 (29.4%)   10 (35.7%)    
  Rb                                                    
   positive                  35 (68.6%)   23 (82.1%)    0.18
   negative                  16 (31.4%)   5 (17.9%)     

DCIS = ductal carcinoma *in situ*; DCIS-Mi = ductal carcinoma *in situ*with microinvasion.

###### 

Relationship among apoptosis-related factors

             **Apoptosis index**   **Survivin**   **Bax**
  ---------- --------------------- -------------- ---------
  Bcl-2      0.11                  0.65           0.042
  Bax        0.018                 0.038          \-
  Survivin   0.077                 \-             \-

Univariate and multivariate analyses for factors affecting invasion
-------------------------------------------------------------------

Univariate analysis for factors affecting invasion beyond the mammary ducts identified the presence of necrosis, positive Bax expression, and positive survivin expression to be significant factors and revealed apoptotic index, positive Bcl-2 expression, and Ki-67 positivity to have a weak correlation with invasion. Multivariate analysis revealed that the presence of necrosis (*P*= 0.017, odds ratio 5.19, 95% Confidence Interval; CI 1.47--22.7), and positive survivin expression (*P*= 0.044, odds ratio 3.98 95%CI 1.11--17.2) were independent factors associated with invasion (Table [6](#T6){ref-type="table"}).

###### 

Univariate and multivariate analyses according to microinvasion

                                                                  Univariate analysis   Multivariate analysis                                          
  --------------------------------------------------------------- --------------------- ----------------------- ----------- ------------ ------------- -----------
                                                                  Odds ratio            95% CI                  *P*-value   Odds ratio   95% CI        *P*-value
                                                                                                                                                       
  Necrosis (present ***vs***. absent)                             5.56                  1.84--20.91             0.0017      5.19         1.45--22.7    0.017
  Apoptotic index (≧1000 of positive cells ***vs***. \< 1/1000)   0.40                  0.14--1.04              0.061       0.82         0.24--2.75    0.74
  Ki-67 index (≧20% of positive cells ***vs***. \< 20%)           0.44                  0.15--1.18              0.10        0.89         0.24--3.24    0.86
  Bcl-2 (positive ***vs***. negative)                             2.57                  0.93--7.95              0.071       3.49         1.04--13.3    0.051
  Bax (positive ***vs***. negative)                               10.92                 2.02--203.9             0.0028      5.21         0.70--111.1   0.16
  Survivin (positive ***vs***. negative)                          4.76                  1.57--17.9              0.0048      3.98         1.11--17.2    0.044

CI, confidence interval

Discussion
==========

The investigation of the biological factors of DCIS-Mi may yield some explanations to the progression from DCIS to IDC. In this study, we examined the intraductal components of both DCIS and DCIS-Mi for expression of these factors, but not the invasive components. The reasons for this were: the purpose of this study was to determine the difference between the intraductal components of DCIS and DCIS-Mi; it was difficult to evaluate invasive foci because of their small size; in some cases, invasive foci were undetectable on slides for immunohistochemical staining; in histological diagnosis, it was important to evaluate the most predominant area of each section. Results from the present analysis showed that the frequency of necrosis was significantly higher in DCIS-Mi compared with DCIS.

The important result obtained from our analysis of apoptosis-related factors was that the positive rate of survivin expression was significantly higher in DCIS-Mi than in DCIS (*P*= 0.0048). The *survivin*gene, shown to be expressed in proliferating cells such as fetal and various cancer cells, is known to be a member of the IAP family which promotes cell proliferation and inhibits apoptosis. In particular, because survivin is expressed specifically in cancer cells and proliferating cells, this gene is likely to be involved in cell proliferation and/or differentiation \[[@B29],[@B30]\].

Previous reports have shown that, in invasive ductal carcinoma of the breast, survivin expression is significantly higher in the invasive foci than in the intraductal components and that high nuclear expression of survivin in the invasive foci is associated with a higher risk of recurrence and mortality \[[@B19],[@B30]\]. However, there have also been reports that showed no correlation between survivin expression and prognosis in patients with breast cancer \[[@B27],[@B31]\], suggesting that its prognostic value is controversial. With the antibody used in this present study, survivin-specific staining in the nucleus was barely detectable, and therefore we relied upon cytoplasmic staining for the evaluation of survivin expression. Reasons for the lack of nuclear expression in this study remain unclear and must be sought in further study on survivin splice variants.

There have been many studies reporting that Bcl-2, an apoptosis inhibitor, shows a positive correlation with hormone receptors in breast cancer tissues and is a favorable prognostic factor \[[@B26]\]. In addition, it has been reported that the expression of an apoptosis promoter Bax is associated with the degree of local recurrence in DCIS \[[@B32]\]. Furthermore, the relation between Bcl-2 and Bax is under debate with some reports showing a direct correlation between them and others showing no such correlation \[[@B33]\].

In our present results, the Bax expression was significantly higher (*P*= 0.0028) and the Bcl-2 expression tended to be slightly higher (*P*= 0.071) in DCIS-Mi compared with DCIS. These results show a positive correlation between Bax and Bcl-2 and their increased expression with the progression from DCIS to DCIS-Mi. Thus, this may suggest that the specific interaction between Bax and Bcl-2 is involved in apoptosis during this progression.

In our present study, we also found a tendency for higher apoptotic and Ki-67 indices in DCIS-Mi relative to DCIS. It is well known that these indices are higher in invasive ductal carcinoma of the breast than in fibroadenoma, a benign breast tumor. In DCIS, it has been shown that proliferation and apoptosis markers are higher in poorly-differentiated tumors than in well-differentiated tumors, which has led some investigators to believe that the difference between DCIS and invasive carcinoma is a relative decrease in apoptosis \[[@B26]\]. Taken together, it has been suggested that both cell proliferation and apoptosis are enhanced in DCIS-Mi as compared to DCIS.

Furthermore, multivariate analysis for apoptosis-related factors affecting invasion, identified the presence of necrosis (*P*= 0.017) and high survivin expression (*P*= 0.044) as statistically significant factors. We also demonstrated that the frequency of apoptosis (*P*= 0.077) and nuclear grade (*P*= 0.081) tended to be higher in cases with positive immunolabeling for survivin, suggesting that survivin could be a marker reflecting the biological characteristics of DCIS and DCIS-Mi. In addition, there was a positive correlation between the expression of the anti-apoptotic factor survivin and that of an apoptosis promoter Bax (*P*= 0.038). These findings suggest that a balance is maintained in DCIS-Mi between survivin and Bax.

These results revealed that, compared to DCIS, DCIS-Mi is histologically associated with necrotic focus more commonly, and with a significantly higher expression of apoptosis-related factors, including survivin and Bax. In other words, DCIS-Mi is characterized by a slightly elevated cell proliferation ability and a tendency for enhanced apoptosis, which could increase cell death and subsequently promote the formation of necrotic foci \[[@B34]\]. In clinical settings, survivin may prove to be a useful marker to indicate a difference in biological features between DCIS and DCIS-Mi, and it could become one of the parameters used to determine whether adjuvant systemic therapy or surviving-inhibiting therapy should be given to patients with DCIS.

Conclusion
==========

Compared with DCIS, DCIS-Mi is characterized by a slightly elevated cell proliferation capacity and enhanced apoptosis within the intraductal lesion, which are thought to promote the formation of cell necrotic foci. Furthermore, survivin is one of the markers indicating the difference in biological features between DCIS and DCIS-Mi, and further investigation of this marker is required to determine if this difference in expression could serve as an indicator for identifying which patients would benefit from adjuvant systemic therapy.
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